Qiming Venture Partners USA is a venture capital firm that invests in early-stage healthcare and technology companies in the United States.

Qiming Venture Partners USA

We know how companies can and should be built.

Founded in 2017, Qiming Venture Partners USA is a healthcare venture capital firm and healthcare investor with a combination of deep technical expertise that allows us to identify tomorrow’s innovations early and strong operational experience with a hands-on approach that makes us the investor of choice for early-stage biotech companies.

Our partners often are sought-after to be on company boards because of their proven, hands-on approach to supporting CEOs and scaling operations. They are trusted business and thought partners.

All of our partners have worked and lived outside of the US, providing us with a true global mindset and our networks are extensive. Only Qiming Venture Partners USA can offer exclusive access and synergy to China, the second-largest healthcare market in the world. We have a unique ability to leverage a world-class China and broader Asian network for market diligence, deal flow, and operational support for portfolio companies.

We harness the deep and highly accretive backgrounds and skillsets of our founders with a next-generation approach through our partners to understand tomorrow’s innovations and reaching across a wide variety of crossover and public investors.

Elevation Oncology

Satellos Bioscience

Talaris Therapeutics

Ventyx Biosciences

HilleVax

Icosavax

Jasper Therapeutics

Congratulations to Umoja Biopharma on their groundbreaking partnership with AbbVie to advance development of in vivo CAR-T therapies for patients in need.

Umoja's VivoVec + RACR/CAR technology enables CAR-T transduction to occur directly in the patient while avoiding challenging chemotherapeutic lymphodepletion regimens, overcoming sizable patient access + manufacturing challenges faced with autologous CAR-T therapies, which are created outside the body. 

Today, we are one significant step closer to a world where more patients, in a safer manner, could be eligible to receive potentially disease-curative medicines. This is made possible by Umoja's outstanding drug development expertise and catalyzed by their state of the art manufacturing capabilities at the CLIMB.

Hearty congrats to the Icosavax, Inc. team on positive data for bivalent RSV / hMPV vaccine and subsequent transaction to AstraZeneca!

https://lnkd.in/gv_x9cZU

COM:QIMINGVCUSA

Qiming Venture Partners USA

Analysis Not Available